Alpha9 Theranostics

Developing two major breakthroughs in tumour targeting that can revolutionize cancer diagnosis and treatment.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Vancouver, BC, Canada
  • Currency USD
  • Founded June 2019
  • Employees 4
  • Incorporation Type Other
  • Website http://In preparation

Company Summary

Alpha9 Theranostics is a biotech company spun out of BC Cancer and the University of British Columbia, pioneering precise radionuclide targeting to cancer. Alpha9 is commercializing breakthrough technology in both cancer treatment and cancer imaging. The technology enables easy one-step attachment of a radionuclide to any cancer-targeting molecule that can be used to both image and treat cancer, especially hard to reach tumours and metastases.

Team

  • Ian McBeath
    CEO

    Over 30 years experience in biopharmaceuticals. Serial entrepreneur and founder of 4 previous biotech companies, one of which was eventually sold to a pharmaceutical company for $1 billion.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free